Participation in Multi Centre Trials in Cardiology.
Effective anticoagulation with Factor xA next generation in Atrial Fibrillation (ENGAGE- AF TIMI-48) IP - EDOXABAN. Phase III. (Principal Investigator).
Evaluate Cardiovascular Outcomes following treatment with Alogliptin in addition to standard of care in subjects with Type 2 Diabetes and Acute Coronary Syndrome. (EXAMINE TRIAL) IP - ALOGLIPTIN. Phase III (Principal Investigator).
Evaluate the Efficacy and Safety of Rivaroxaban in Subjects with a Recent Acute Coronary Syndrome (ATLAS ACS 3001) IP - RIVAROXABAN. Phase III. (Principal Investigator). 2010-2011. (Study completed in October 2011).
Subcutaneous Canakinumab in the prevention of recurrent cardiovascular events among stable post-myocardial infarction patients with persistently elevated hsCRP (CANTOS STUDY)
Evaluation of the Anti- Anginal efficacy and safety of oral administration of Ivabradine compared to placebo on top of a background therapy with a Calcium Antagonist in patients with stable Angina Pectoris (CL3-16257-068) I P - IVABRADINE. Phase III. (Sub Investigator). 2009.
Your participation in the survey will help other patients make informed decisions. You will also be helping Dr. Jabir Abdullakutty and his staff know how they are doing and how they can improve their services.
How was your experience with Dr. Jabir Abdullakutty?
Help other patients, and let the doctor know how he's doing